This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The FDA approved BridgeBio s first drug, for a disease that affects 100 children in the US and Europe.
BridgeBio mitigates risk with a hub-and-spoke model, with a central management team and subsidiaries.
The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says.
It wasn t that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts.
But these days, CEO Neil Kumar says he s taking calls from industry insiders interested in launching companies emulating the BridgeBio model. If it helps patients, he s willing to guide rivals.
âWhen the spotlight found Moderna, they were readyâ: How the Cambridge biotech company became a world renowned success story
By Scott Kirsner Globe Correspondent,Updated December 18, 2020, 7:11 p.m.
Email to a Friend
A year ago, Moderna was not on anyoneâs âMost Likely to Succeedâ list.
As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors werenât particularly hot on its potential, either â after going public in December 2018, Modernaâs stock price hadnât done much over the ensuing 12 months.
There was skepticism about the companyâs approach â using custom-crafted RNA to instruct the bodyâs cells to battle a disease or virus â partly because Moderna hadnât disclosed much data about it. And there were questions about its focus on a dim corner of the biotechology industry that, in the words of biotech entrepreneur and
‘When the spotlight found Moderna, they were ready’: How the Cambridge biotech company became a world renowned success story Scott Kirsner
A year ago, Moderna was not on anyone’s “Most Likely to Succeed” list.
Popular Searches
As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors weren’t particularly hot on its potential, either ― after going public in December 2018, Moderna’s stock price hadn’t done much over the ensuing 12 months.
There was skepticism about the company’s approach using custom-crafted RNA to instruct the body’s cells to battle a disease or virus ― partly because Moderna hadn’t disclosed much data about it. And there were questions about its focus on a dim corner of the biotechology industry that, in the words of biotech entrepreneur and former Biogen research executive Michael Gilman, was “neither sexy nor lucrative” �